More on Pharmacyclics (PCYC): FQ2 beats on both sales and EPS expectations. Revenue for the...


More on Pharmacyclics (PCYC): FQ2 beats on both sales and EPS expectations. Revenue for the quarter consisted primarily of $50M in milestone revenue due to hitting a clinical milestone in connection with it's collaboration and license agreement with Janssen Biotech, plus $5M of license revenue related to its license agreement with Novo Nordisk under which Novo acquired exclusive worldwide rights to its small molecule Factor VIIa inhibitor, PCI-27483, for a restricted disease indication outside of oncology.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs